FEMTELLE® and uPA/PAI-1 Biomarker References
Reviews
- Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to Level 1 Evidence studies. Clin Chem. 2002;48:1194–1197.
- Harbeck N, Kates RE., Gauger K., et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost. 2004;91:450-456
- Harbeck N, Kates RE, Schmitt M, et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004;5:348-352.
- Harbeck N, Schmitt M, Paepke S, et al. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci. 2007;44:179-201.
- Annecke K, Schmitt M, Euler U, et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem. 2008;45:31-45.
- Harbeck N, M. Schmitt, S. Paepke and H. Allgayer. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit. Rev. Clin. Lab. Sci. 2007;44:179-201.
- Schmitt M, K. Mengele, A Gkazepis et al. Assessment of urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer tissue: Historical aspects and future prospects. Breast Care 2008;3:3-10.
Methods
- Schmitt M, Sturmheit AS, Welk A, et al. Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA. Methods Mol Med. 2006;120:245-265.
- Schmitt M, Mengele K, Schueren E, et al. European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur J Cancer. 2007;43:835-844.
- Biermann JC, Holzscheiter L, Kotzsch M, et al. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med. 2008;21:251-259.
- Thomssen C, Harbeck N, Dittmer J et al. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. J. Nat’l Cancer Inst. 2009;101:1028-1029.
Key Clinical Studies
- Harbeck N, Dettmar P, Thomssen C, et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer. 1999;80:419-426.
- Janicke F, Prechtl A, Thomssen C, et al. German N0 Study Group. Randomized adjuvant chemotherapy trial in high risk,lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst. 2001;93:913-920.
- Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116-128.
- Look M, van Putten W, Duffy M, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients Thromb Haemost. 2003;90: 538-548.
- Harbeck N, Kates RE, and Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol. 2002;20:1000-1007.
- Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 2003;21:1022-1028.
- Subramaniam DS and C. Isaacs. Utilizing Prognostic factors in breast cancer. Current Treat. Options in Oncol. 2005;6:147-159.
- Vetter M, C Thomssen, E Kantelhardt. Risk assessment in node-negative breast cancer by the invasion factors uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1. Correlation to the tumor characteristics in the prospective NNBC 3-Europe trial. At San Antonio Breast Cancer Symposium 2009. Abstr. 4040.
- Harbeck N, M. Schmitt, M. Vetter et al. Prospective biomarker trials chemo N0 and NNBC-3 Europe validate the clinical utility of invasion markers uPA and PAI-1 in node-negative breast cancer. Breast Care 2008;3:11-15.
